BRCA2 and neoplasm: Treatment with each of the three drugs showed tumour growth inhibition at the nadir of the effect of 89, 89 and 85%, respectively (Table 1), with a progression‐free survival of 19, 21 and 24 days, suggesting similar anti‐tumoral activities against BRCA2‐defective tumours.